

=====

-----

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K  
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  
August 15, 2007

AVANT IMMUNOTHERAPEUTICS, INC.  
(Exact name of registrant as specified in charter)

Delaware  
(State or other  
jurisdiction  
of incorporation)

0-15006  
(Commission file number)

13-3191702  
(IRS employer  
identification no.)

119 Fourth Avenue  
Needham, Massachusetts 02494-2725  
(Address of principal executive offices) (Zip code)

Registrant's telephone number, including area code:  
(781) 433-0771

-----

Check the appropriate box below if the Form 8-K filing is intended to  
simultaneously satisfy the filing obligation of the registrant under any of the  
following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17  
CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR  
240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the  
Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the  
Exchange Act (17 CFR 240.13e-4(c)) LIBC/3057888.2

-----

=====

Item 3.01-Notice of Delisting or Failure to Satisfy a Continued Listing Rule or  
Standard; Transfer of Listing.

On August 15, 2007, AVANT Immunotherapeutics, Inc. (the "Company")  
received a letter from the Listing Qualifications Department of The NASDAQ Stock  
Market indicating that the Company is not in compliance with NASDAQ Marketplace  
Rules 4450(b)(1)(A) and (B) because the Company's market value and total assets  
and revenue have been below the minimum \$50,000,000 requirement for the last 10  
consecutive trading days. This notification has no effect on the listing of the  
Company's common stock at this time. The Company will have 30 calendar days, or  
until September 14, 2007, to regain compliance in accordance with Marketplace  
Rule 4450(e)(4). The Company will seek to regain compliance within the 30-day  
cure period.

To regain compliance, on August 20, 2007, the Company applied to list its  
common stock on the NASDAQ Capital Market and NASDAQ will determine whether the  
Company meets the NASDAQ Capital Market continued listing criteria. Because the  
Company has submitted a transfer application to the NASDAQ Capital Market before  
September 14, 2007, the initiation of the delisting proceedings will be stayed  
pending NASDAQ's review of the application.

On August 21, 2007 the Company issued a press release announcing its receipt of the notification letter. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description of Exhibit
99.1	AVANT Immunotherapeutics, Inc. Press Release, dated August 21, 2007

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AVANT IMMUNOTHERAPEUTICS, INC.

Dated: August 21, 2007

By: /s/ Avery W. Catlin

-----  
Avery W. Catlin  
Title: Senior Vice President and  
Chief Financial Officer

EXHIBIT INDEX

The following designated exhibit is furnished herewith:

Exhibit Number	Description of Exhibit
99.1	AVANT Immunotherapeutics, Inc. Press Release, dated August 21, 2007

## AVANT Receives NASDAQ Deficiency Notice Relating to Market Value

NEEDHAM, Mass.--(BUSINESS WIRE)--Aug. 21, 2007--AVANT Immunotherapeutics (Nasdaq: AVAN) announced today that on August 15, 2007 it received a letter from The NASDAQ Stock Market stating that for the last 10 consecutive business days, the market value for AVANT's common stock has been below the \$50,000,000 minimum requirement for continued inclusion under NASDAQ Marketplace Rule 4450(b)(1)(A) and that AVANT's total assets and revenue were below the \$50,000,000 requirement under Rule 4450(b)(1)(B).

In accordance with NASDAQ Marketplace Rule 4450(e)(4), AVANT has 30 calendar days, or until September 14, 2007, to regain compliance by maintaining the market value of its listed common stock at \$50,000,000 or more for a minimum of 10 consecutive business days or, alternatively, AVANT may apply to transfer for listing on the NASDAQ Capital Market. The NASDAQ letter has no effect on the listing of AVANT's common stock at this time.

AVANT has sought to regain compliance within this cure period by applying to transfer the listing of its common stock to The NASDAQ Capital Market. The initiation of the delisting proceedings will be stayed pending NASDAQ's review of AVANT's transfer application, which was submitted on August 20, 2007. There can be no assurance that NASDAQ will grant AVANT's request for transfer as a result of this process. In addition, AVANT has retained Needham & Company, LLC to assist AVANT in evaluating other strategic alternatives.

Additional information on AVANT Immunotherapeutics, Inc. can be obtained through our site on the World Wide Web:  
<http://www.avantimmune.com>.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that are subject to a variety of risks and uncertainties and reflect AVANT's current views with respect to future events and financial performance. There are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking statement made by AVANT. These factors include, but are not limited to: (1) the integration of multiple technologies and programs; (2) the ability to adapt AVANT's vectoring systems to develop new, safe and effective orally administered vaccines against anthrax and plague or other any other microbes used as bioweapons and other disease causing agents; (3) the ability to successfully complete product research and further development, including animal, pre-clinical and clinical studies, and commercialization of CholeraGarde(R) (Peru-15), Ty800, ETEC E. coli vaccine, VLPs and other products and AVANT's expectations regarding market growth; (4) the cost, timing, scope and results of ongoing safety and efficacy trials of CholeraGarde(R) (Peru-15), Ty800, ETEC E. coli vaccine and other preclinical and clinical testing; (5) the ability to negotiate strategic partnerships or other disposition transactions for AVANT's cardiovascular programs, including TP10 and CETi; (6) the ability of AVANT to manage multiple clinical trials for a variety of product candidates; (7) AVANT's expectations regarding its technological capabilities and expanding its focus to broader markets for vaccines; (8) the Company's expectations regarding the cost of funding its development partnership with Select Vaccines Limited for the influenza vaccine, the opportunity to extend to other disease targets, and AVANT's ability to develop products through this collaboration; (9) changes in existing and potential relationships with corporate collaborators; (10) the availability, cost, delivery and quality of clinical and commercial grade materials produced at AVANT's own Manufacturing facility or supplied by contract manufacturers and partners; (11) the timing, cost and uncertainty of obtaining regulatory approvals; (12) the ability to develop and commercialize products before competitors that are superior to the alternatives developed by competitors; (13) the ability to retain certain members of management; (14) AVANT's expectations regarding research and development expenses and general and administrative expenses; (15) AVANT's expectations regarding cash balances, capital requirements, anticipated royalty payments (including those from Paul Royalty Fund), revenues and expenses, including infrastructure expenses; (16) our belief regarding the validity of our patents and potential litigation; and (17) certain other factors that might cause AVANT's actual results to differ materially from those in the forward-looking statements including those set forth under the headings "Business," "Risk

Factors" and Management's Discussion and Analysis of Financial Condition and Results of Operations" in each of AVANT's Annual Report on Form 10-K, its Quarterly Reports on Form 8-K, as well as those described in AVANT's other press releases and filings with the Securities and Exchange Commission, from time to time. You should carefully review all of these factors, and you should be aware that there may be other factors that could cause these differences. These forward-looking statements were based on information, plans and estimates at the date of this press release, and AVANT does not promise to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other changes.

CONTACT: AVANT Immunotherapeutics, Inc.  
Una S. Ryan, Ph.D., 781-433-0771  
President and CEO  
or  
Avery W. Catlin, 781-433-0771  
Chief Financial Officer  
info@avantimmune.com  
or  
For Media:  
Kureczka/Martin Associates  
Joan Kureczka, 415-821-2413  
jkureczka@comcast.net